Glenmark Pharmaceuticals Limited Annual Report FY2026
Glenmark Pharmaceuticals Limited Annual Report FY2026
Quality Scores
Latest Quarterly Earnings Summary
Loading latest quarter…
AI Summary
Glenmark Pharmaceuticals is a global research-led pharmaceutical player with a strong presence in the US, India, and Europe. Over the last decade, the company has transitioned from a high-growth generic player to a specialty and innovation-focused firm. While the company maintains top-tier market rankings, its financial performance has been marred by high R&D intensity and inconsistent profitability. Recent divestments, specifically the stake sale in Glenmark Life Sciences, have significantly deleveraged the balance sheet, a major historical overhang. However, operational volatility remains a…
Key Changes in FY2026
Glenmark has successfully transitioned from a domestic formulations player to a global specialty pharma entity focusing on dermatology, respiratory, and oncology. The 10-year timeline showcases a shift from basic generics to complex ANDAs and New Molecular Entities (NME) through its subsidiary Ichnos. The launch of Ryaltris globally marks a significant move up the value chain toward branded specialty assets. The company is actively premiumizing its portfolio in India, particularly in the cardiac and diabetes segments, where it holds significant market share. Geographically, it has reduced its over-reliance on the US market by expanding its European and Emerging Market footprints. Digital transformation is evident in its manufacturing automation and enhanced field force productivity…
Management Commentary
Management demonstrates deep technical expertise and a clear vision for moving up the value chain toward specialty dermatology and respiratory products. They have successfully built a Top-15 generic business in the US and remains a Top-5 Indian player in Europe. Transparency is reasonable through detailed investor presentations and consistent quarterly concalls. However, management has faced challenges in containing costs and managing the working capital cycle, which has consistently been longer than the industry median. The ability to pivot the business model during the FY24-25 period shows strategic agility, but execution on PAT stability remains unproven.
Financial Highlights
Revenue growth has been moderate with an 8% CAGR over 10 years, though recent performance shows a sharp uptick with TTM sales at ₹16,983 Cr. Operating margins have historically fluctuated between 14-22%, recently spiking to 27% due to one-off events and product launches. Net profit has been highly volatile, evidenced by a massive loss in Mar 2024 (₹1,434 Cr) followed by a sharp recovery. The company's tax rate is frequently inconsistent, reaching an abnormal 430% in FY24, suggesting significant deferred tax adjustments or write-offs. Despite the volatility, the company maintains a healthy ROCE of 39.8% in its current cycle, indicating strong return potential on current assets.
Major Opportunities
- Significant net debt reduction to near debt-free status
- Strong recovery in OPM to 27% in recent periods
- 14th largest player in India with fast-growing domestic franchise
Major Risks
- Highly volatile historical Net Profit and EPS
- Persistent issues with Working Capital (CCC at 83-147 days)
- High Inventory days (264 days) causing liquidity drag
About This Annual Report
The Glenmark Pharmaceuticals Limited FY2026 Annual Report is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis (MD&A), audited financial statements, director's report, corporate governance report, auditor's report, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This page consolidates the official PDF and an AI-generated summary so investors can quickly grasp what changed vs. prior years — sales growth, margin trend, cash flow quality, capex, dividends and management outlook — without having to read the entire filing.
Why Use AI?
- Summarises hundreds of pages into a focused executive briefing
- Identifies year-on-year key changes automatically
- Extracts management commentary and tone
- Highlights top risks and opportunities
- Compares business evolution vs. earlier years
- Answers your questions in plain English via Ask AI
Frequently Asked Questions
Related Research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.